Table 6. Summary of the major findings.

	Trend (P<0.05)
Cancer sites (ICD 9th revision)	With time since NHL diagnosis	With age at NHL diagnosis	With calendar period at NHL diagnosis	Risk of NHL as a second primary cancer and trend with time since the first cancer (P<0.05)	Comments
Lip (140)	—	—	↗	1.16 (0.96–1.38) No trend	Common exposure or mechanism
Tongue (141)	—	—	—	1.43 (0.95–2.06) No trend	Common exposure or mechanism
Oropharynx (146)	—	—	—	2.75 (1.84–3.94) No trend	Common exposure or mechanism
Stomach (151)	↗	↘	—	1.14 (0.97–1.34) ↗	Treatment effect or misclassification of extranodal NHL
Small intestine (152)	—	—	—	1.36 (0.81–2.15) No trend	Detection bias
Colon (153)	—	—	—	1.16 (1.06–1.26) No trend	Misclassification of extranodal NHL
Liver (155) (−155.2)	—	—	—	0.79 (0.26–1.85) No trend	Common exposure or mechanism
Nose and nasal cavity (160)	—	—	—	1.79 (1.14–2.69) No trend	Common exposure or mechanism
Lung (162)	↗	↘	—	1.12 (0.98–1.27) No trend	Treatment effect +common exposure
Soft tissue sarcoma (171)	—	—	—	1.84 (1.43–2.33) No trend	Common exposure or mechanism
Melanoma of skin (172)	↘	—	—	1.42 (1.29–1.57) ↘	Common exposure or mechanism
Other neoplasm of skin (173)	—	—	—	1.90 (1.79–2.01) ↘	Common exposure or mechanism
Bladder (188, 189.3, 189.4)	↗	↘	—	1.15 (1.04–1.26) No trend	Treatment effect +common exposure
Kidney (189) (−189.3, 189.4)	—	—	↗	1.25 (1.07–1.46) No trend	Detection bias
Thyroid gland (193)	—	—	—	1.68 (1.37–2.04) No trend	Common exposure or mechanism
Hodgkin's disease (201)	↗	↘	—	6.30 (5.39–7.32) No trend	Treatment, common exposure or misclassifciation
Lymphoid leukaemia (204)	—	↘	—	3.19 (2.76–3.67) No trend	Misclassification and common exposure
Myeloid leukaemia (205)	—	↘	—	1.54 (0.96–2.33) No trend	Treatment effect

NHL, non-Hodgkin's lymphoma.